Elior Drori1, Shai Berman1, and Aviv Mezer1
1The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel
Synopsis
The striatum is a heterogeneous brain structure
with microstructural gradients along its main axes. Changes in its organization
are associated with Parkinson’s disease (PD). Yet the spatial variability in
the human striatum is not well characterized and is mostly limited to animal
and postmortem studies. We developed a non-invasive MRI method for measurement
of microstructural gradients along axes of the striatum in individuals in
vivo. Using clinical data, we found a T1w/T2 gradient along the
anterior-posterior axis of the putamen, which is decreased in PD. This decrease
explains the patients’ asymmetries in dopamine loss and motor symptoms.
Introduction
The striatum is involved in motor control
and goal-directed behavior, which are affected in neurodegenerative diseases
such as Parkinson’s disease1. While the typical striatal tissue is characterized by heterogeneous
organization, spatially-dependent changes are apparent in PD, mainly along the
striatum’s anterior-posterior axis, with acute degeneration in posterior parts
of the putamen2,3. This degeneration is characterized by the depletion of
dopaminergic innervation to the striatum, often asymmetrically between
hemispheres. However, the striatal tissue composition is studied mainly using
invasive animal research and human postmortem methods, and the
relationship between dopamine loss, tissue deterioration and motor disfunction
in PD is not well characterized in vivo. We
have recently developed a non-invasive tool for quantifying structural
heterogeneity along axes of the human striatum of individuals, using quantitative
MRI4. Here, we use this method to detect abnormal, spatially
dependent PD-related changes in the striatum, using a semi-quantitative MRI
contrast, generated from widely available clinical data. We further investigate
the relationship between local alterations and dopamine loss, measured by SPECT
DaTSCAN, as well as the motor symptoms assessed through the MDS-UPDRS III5. We show that asymmetries in structural deterioration are
associated with dopamine loss in the putamen ipsilaterally, and with motor
disfunction contralaterally. Hence, we provide a non-invasive method to link
structure, function, and behavior in individual PD patients. Since our approach
exploits MRI data that is widely used in clinical settings, it may prove useful
for wide clinical and diagnostic applications.Methods
Subjects and data. Data obtained from the Parkinson’s Progression Markers Initiative
(PPMI) database (www.ppmi-info.org/data).
We analyzed 99 older, early-stage PD patients (aged 65 ± 6 years, range 55-76;
32 female), Hoehn and Yahr Scale’s stage 1 (N=40) or stage 2 (N=59).
46 healthy controls were matched for age and sex (aged 65 ± 6 years, range
55-76; 17 female). T1w and T2w images were acquired for all subjects with a 3T
MRI scanner. Using these images, we generated a semi-quantitative T1w/T2w
contrast that minimized the shared bias of
the weighted images. Subcortical brain segmentation was done using FSL FIRST6.
Dopamine transporter binding ratio. SPECT DaTSCAN was performed on all subjects for assessment of dopamine
transporter (DAT) deficit, and the striatal binding ratio (SBR) was calculated
for the putamen and caudate. Dopamine loss asymmetry was calculated for each
subject as the left-minus-right SBR.
Motor assessment. Motor symptoms were assessed through MDS-UPDRS-III. The
motor symptoms asymmetry was calculated as the raw score for left body-side
items minus the raw score for right body-side items.
Structural
gradients of the striatum. We developed4 an automated MATLAB-implemented tool
to compute the three main orthogonal axes of each individual’s subcortical
structures, using SVD. The structure (e.g., left putamen) is then segmented to
equally spaced segments along each axis, and the MRI values are then sampled
along them. This yield structural MRI profiles which are functions of position
along the main axes of the subject’s striatum.Results
In healthy controls (HC; N=46) we found a robust,
increasing T1w/T2w gradient along the anterior-posterior (AP) axis of the left
and right putamen (mixed-effects linear model, p <10-67; Fig. 1a). This gradient
was correlated with quantitative R1 AP gradient that we have found previously4,
suggesting that T1w/T2w gradients in the striatum reflect spatial variation in
tissue biophysical properties (Fig. 1b). In early-stage PD patients (N=99), however, we found alterations
in the structural gradient, expressed as a reduction in the posterior
subregions of the putamen (p <.05; Fig. 2a). On the single-subject level, we found
that interhemispheric asymmetry in T1w/T2w intensity was positively correlated
with ipsilateral asymmetry in dopamine transporter striatal binding ratio (DaT
SBR). Namely, a greater T1w/T2w decrease in the posterior putamen in one
hemisphere relative to the other was associated with a greater decrease of the
DaT SBR in the putamen of that same hemisphere (R2 =.25, p <10-7; Fig. 2b). Moreover, we found
that the gradient asymmetry was positively correlated with contralateral
asymmetry in the patients’ motor symptoms, as assessed using the MDS-UPDRS III
(R2
=.25, p <10-7; Fig.
2c, e). Interestingly, this relationship could not be found using conventional
whole-ROI mean statistics (R2
=.01, p =0.4; Fig. 2d).
Hence, using our spatial approach with non-invasive MRI clinical data, we found
a novel in vivo correlate for PD, associated with the individual
patients’ underlying dopaminergic loss and the motor symptomatology.Conclusions
Our study suggests that tissue microstructure
gradients can be detected along the main axes of the striatum using T1w/T2w
contrast. Importantly, these gradients show a local alteration in the posterior
putamen in early-stage PD patients. This PD-related structural abnormality is
associated with both the asymmetric decrease in dopamine transporter binding
ratio, measured with SPECT, and the PD-related asymmetric motor decline,
assessed with MDS-UPDRS III. Hence, our approach opens a venue towards an early
non-invasive characterization of PD neural correlates in individual patients
and may promote early diagnosis and personalized medicine in PD. Future
research using quantitative MRI measurements may shed further light on the
biological mechanisms underlying the structural changes in PD, as well as in
other basal-ganglia disorders.Acknowledgements
No acknowledgement found.References
-
Redgrave,
P. et al. Goal-directed and habitual control in the basal ganglia:
Implications for Parkinson’s disease. Nature Reviews Neuroscience vol.
11 760–772 (2010).
- Moratalla, R. et
al. Differential vulnerability of primate caudate-putamen and
striosome-matrix dopamine systems to the neurotoxic effects of
1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc. Natl. Acad. Sci. U. S.
A. 89, 3859–3863 (1992).
- Garnett, E.
S., Lang, A. E., Chirakal, R., Firnau, G. & Nahmias, C. A rostrocaudal
gradient for aromatic acid decarboxylase in the human striatum. Can. J.
Neurol. Sci. 14, 444–447 (1987).
- Drori, E.,
Filo, S. & Mezer, A. Measuring Biological Gradients along the Human Dorsal
Striatum in vivo using Quantitative MRI. in ISMRM Annual Meeting (2020).
- Goetz, C. G. et
al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing
results. Mov. Disord. 23, 2129–2170 (2008).
- Patenaude, B.,
Smith, S. M., Kennedy, D. N. & Jenkinson, M. A Bayesian model of shape and
appearance for subcortical brain segmentation. Neuroimage 56,
907–922 (2011).